Alexion Pharma Spain, S.L. - Sucursal Em Portugal
Alexion Pharma Spain, S.L. - Sucursal Em Portugal, a subsidiary of Alexion Pharmaceuticals, Inc., is strategically headquartered in Portugal, serving as a vital hub for the company’s operations across the Iberian Peninsula. Founded in 1992, Alexion has established itself as a leader in the biopharmaceutical industry, focusing on innovative therapies for rare diseases and complex conditions. The company is renowned for its core products, including Soliris and Ultomiris, which are unique in their ability to target specific pathways in the immune system, offering transformative solutions for patients with severe and life-threatening disorders. With a strong market position, Alexion has achieved significant milestones, including numerous regulatory approvals and a commitment to advancing patient care through research and development.
DitchCarbon Score
How does Alexion Pharma Spain, S.L. - Sucursal Em Portugal's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Alexion Pharma Spain, S.L. - Sucursal Em Portugal's score of 53 is higher than 88% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Alexion Pharma Spain, S.L. - Sucursal Em Portugal's reported carbon emissions
Alexion Pharma Spain, S.L. - Sucursal Em Portugal currently does not have available carbon emissions data for recent years, as no specific emissions figures have been provided. Consequently, there are no reported Scope 1, 2, or 3 emissions figures to analyse. In terms of climate commitments, there are no documented reduction targets or initiatives outlined in the available information. This absence of data suggests that the company may still be in the early stages of establishing its climate strategy or reporting framework. As the pharmaceutical industry increasingly prioritises sustainability, it is essential for companies like Alexion Pharma to develop and communicate clear climate commitments and reduction targets to align with global efforts to mitigate climate change.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Alexion Pharma Spain, S.L. - Sucursal Em Portugal is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
